McCormick (MKC) stock analysis — $65B Unilever Foods merger, Frank's RedHot, Cholula, Old Bay, French's mustard, B2B Flavor Solutions, 39-year dividend growth (Dividend Aristocrat). Is MKC a buy at $46.83 in 2026?
Clorox (CLX) stock analysis — full recovery from the Aug 2023 cyberattack, IGNITE strategy, Glad/Brita/Burt's Bees portfolio strength, 49-year dividend streak, CEO transition, and valuation at $96. Is CLX a buy in 2026?
TROW T. Rowe Price stock outlook 2026: 40 consecutive years of dividend increases, $1.83T AUM, Q1 2026 net outflows $13.7B, ETF franchise crossing $25B, retirement plan stickiness, 5.1% yield at 10.9x P/E. Is the discount a trap or opportunity?
Gilead Sciences (GILD) stock outlook 2026: Biktarvy $3.4B quarterly, Yeztugo $166M debut, anito-cel CAR-T PDUFA Dec 23, 2026, 2.46% dividend yield, analyst target $152. Full pipeline, risks, and 3 price scenarios for US investors.
Duke Energy (DUK) 2026 analysis: data center load growth in the Carolinas, rate base CAGR, 40-year dividend record, coal retirement timeline, and 12-month price targets.
A deep-dive into CVS Health (CVS) stock in 2026 — Aetna MLR pressure, Oak Street Health economics, Caremark PBM regulation risk, dividend sustainability, and 12-month price targets.